Here is a selection of the ads that have (or will) move the prices of these companies:
(Come back and read us from time to time
so you don’t miss an update)
British Swedish Pharmaceutical Group AstraZeneca (AZN, $60.79) announced Tuesday that it has received the green light from the European Commission for its proposed $39 billion acquisition of US biotech company Alexion. The endorsement given by Brussels for this process follows those already won by the United States and Japan, as well as in other countries, according to a press release. AstraZeneca still has to get UK approval, with the Competition Authority (CMA) launching an investigation into the matter in May. The CMA must determine by July 21 whether it decides to start an in-depth investigation and in this case the project can be demanded, through transfers for example. With this green light from the European Union, “we are a little closer to completing this acquisition, which would create a pioneer in immunology and precision medicine,” confirms Mark Dunwer, AstraZeneca’s chief financial officer. The manager believes that the process should be completed as planned during the quarter. Announced in December, the acquisition of the US biotech company specializing in rare diseases was almost unanimously announced by shareholders. AstraZeneca states that research in the field of rare diseases is in full development. There are more than 7,000 of them, and only 5% of them have a treatment approved by the US Medicines Agency (FDA).
US Fund platinum royalties The chemist will get $5.25 billion Solines, 49% owned by the German giant sorry (BASF.TI, €67.26) and 51% of the fund Clayton, Dobellier and Rice, according to a statement issued Tuesday. “The transaction includes a foundation value of Solenis of $5.25 billion, an amount that takes into account net debt of $2.5 billion,” BASF said. In 2018, the German chemical group entered into an agreement to purchase 49% of Solenis shares from the Clayton, Dubilier & Rice fund that owns it. The purpose of the deal was for BASF to combine its paper and water processing activities with the American company, one of the world’s specialized companies in this field. The new entity operates as a joint venture, jointly between BASF and Clayton Fund, Dubilier & Rice, but operates under the Solenis name. According to the deal announced Tuesday, the two former partners are “completely withdrawing from Solenis,” whose 100% ownership will pass to Platinium Equity. “The sale is supposed to be completed before the end of 2021,” BASF said. “The deal does not affect any of the supply agreements and commercial relations between BASF and Solenis,” the German group said. Platinium Equity is a California investment fund established in 1995, with offices in New York, London and Singapore in particular. On the other hand, Solenis is headquartered in the US state of Delaware and employs approximately 5,200 people.
car maker Stilants (STLA, $19.76) will invest £100 million to sustain its historic Vauxhall plant in northwest England, and shift it towards “100% electric” production of trucks, the group announced on Tuesday. As of the end of 2022, the site at Ellesmere Port will produce eight models of electric trucks: four “light commercial vehicles” (Vauxhall Combo-e, Opel Combo-e, Peugeot e-Partner and Citroën e- Berlingo) and four of them copied into automobiles. Passengers (Vauxhall Combo-e Life, Opel Combo-e Life, Peugeot e-Rifter, Citroën e-Berlingo), Stellantis detailed in a statement. The group also said: “With the support of the British government, Stellantis is investing £100 million to ensure a 100% electric future for the station” built in 1962, without giving further details on the content of the government’s “subsidy”. Stellantis had been proclaiming for several months that the future of Ellesmere Port was at stake and that one option was to build an electric car there, provided it had significant support from the British government, which wanted to ban the sale of petrol cars in the UK from 2030. There are about 1,000 jobs Directly at stake and according to the union, 7,000 indirect jobs in the UK supply chain are consolidated. The future of the plant was called into question after Stellantis announced that its new Astra model would not be made there.